Pantoprazole niche among the GERD-medicines

Main groups of antisecretory drugs used in the treatment of acid-dependent diseases, including gastroesophageal reflux disease (GERD), are described in a review. Mechanisms of activation, degradation and inactive metabolites formation of proton pump inhibitors (PPIs) – final elements of acid production blockage – are considered in detail. Special attention is paid to the presence of PPIs’ derivatives with different functional activity: inactive derivatives, active and inactive metabolites. Topographic description of these derivatives, their significance in terms of an effect on bioavailability, clinical effectiveness and a potential of PPIs interactions with other administered drugs. The combined decision-making algorithm in the presence of gastroesophageal reflux disease symptoms is presented, compiled on the basis of the most authoritative current recommendations. This algorithm provides for the use of PPIs in standard doses once a day for 4–8 weeks with a possible dose escalation in a case of ineffectiveness. If treatment with high doses of PPIs is ineffective, a set of measures is needed to identify the causes of this inefficiency and to choose additional medical strategy. Depending on the clinical situation, after erosions epithelization the treatment can be stopped, used on demand, prolonged in the intermittent or supportive forms. Particular attention is paid to the Panum® drug, which has proven its effectiveness in patients with different degrees of reflux esophagitis. The availability of dosage forms for prescription and over-the-counter leave allows ensuring its comfortable and unhindered purchase by patients and eliminating excessive burden on the healthcare system.

1. Ruffin J.M., Texter E.C. Jr., Carter D.D., Baylin G.J. Role of Anticholinergic Drugs in Treatment of Peptic Ulcer. JAMA. 1953;153(13):1159–1161. doi: 10.1001/jama.1953.02940300017005.

2. Einsel I.H., Lloyd A.W., Myers V.C. Aluminum hydroxide in the treatment of peptic ulcer. Am J Dig Dis. 1934;1:513–516. doi: 10.1007/bf02998966.

3. Kukes V.G., Starodubtsev A.K., Shykh Ye.V. (eds.) Сlinical pharmacology pharmacotherapy. 4th ed. Moscow: GEOTAR-Media; 2020. 880 p. (In Russ.) doi: 10.33029/9704-5279-0-KFF-2020-1-880.

4. Gupta H.P., Saini K., Dhingra P., Pandey R. Study of Acid Catalyzed Reactions of Proton Pump Inhibitors at D.M.E. Portugaliae Electrochimica Acta. 2008;26(5):433–448. Available at: http://www.peacta.org/articles_upload/PEA_26_5_433_448.pdf.

5. Berthelette K.D., Swann T., Fountain K.J. Forced Degradation Analysis of Omeprazole Using CORTECS 2.7 µm Columns. Waters; 2014. 5 p. Available at: https://www.waters.com/waters/library.htm?cid=511436&lid=134806927&locale=ru_RU.

6. Roche V.F. Teachers’ topics. The Chemically Elegant Proton Pump Inhibitors. Am J Pharm Educ. 2006;70(5):101. doi: 10.5688/aj7005101.

7. Shykh E.V. (ed.) Gastroesophageal reflux disease: clinical manifestations, drug therapy. Moscow: GEOTAR-Media; 2019. 160 p. (In Russ.)

8. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Y.K., Dronova O.B., Zayratyants O.V. et al. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75–95. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/513/344.

9. Sandhu D.S., Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut and Liver. 2018;12(1):7–16. doi: 10.5009/gnl16615.

10. Iwakiri K., Kinoshita Y., Habu Y., Oshima T., Manabe N., Fujiwara Y. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–767. doi: 10.1007/s00535-016-1227-8.

11. Savarino E., Zentilin P., Marabotto E., Bodini G., Della Coletta M., Frazzoni M. et al. A Review of Pharmacotherapy for Treating Gastroesophageal Reflux Disease (GERD). Expert Opin Pharmacother. 2017;18(13):1333–1343. doi: 10.1080/14656566.2017.1361407.

12. Gyawali C.P., Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154(2):302–318. doi: 10.1053/j.gastro.2017.07.049.

13. Vaezi M.F., Pandolfino J.E., Vela M.F., Shaheen N.J. White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2017;15(8):1162–1172. doi: 10.1016/j.cgh.2017.03.021.

14. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2013;108(3):308–328. doi: 10.1038/ajg.2012.444.

15. Masharova A.A., Yanova O.B., Valitova E.R., Kim V.A., Zelenikin S.A. Panum (pantoprazole) effectiveness in the treatment of patients with GERD. Ehksperimentalnaia i klinicheskaia gastroenterologiia = Experimental & Clinical Gastroenterology. 2011;(4):81–85. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22663368.

16. Minushkin O.N., Maslovskiy L.V., Loginov V.A., Osin V.A., Mayorova E.M. Experience of using Panum (pantoprazole) in the treatment of erosive and non-erosive reflux disease. Ehffektivnaya farmakoterapiya. Gastroehnterologiya = Effective Pharmacotherapy. Gastroenterology. 2010;(6):28–32. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21836947.